Amgen has entered into an agreement with F. Hoffmann-La Roche to acquire Roche’s rights to filgrastim and pegfilgrastim in approximately 100 markets, effective January 1, 2014. The products are white blood cell boosting therapeutics used to reduce the risk of infection in patients receiving chemotherapy. They’re marketed by Amgen in the U.S. and Europe under the trade names Neupogen and Neulasta, respectively.   Roche has held the rights to filgrastim and pegfilgrastim since 1989 under lic...